Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 2/20 | 0.38 |
| ▸ | ALB | P02768 | 2/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.35 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.35 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.35 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.34 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12127948 | 0.98 | TTR (0.37) | TTRALBCYP11B1CYP11B2MGLL | |
| SCHEMBL23072580 | 0.92 | ALDH1A1 (0.44) | MGLLALDH1A1 | |
| SCHEMBL12127900 | 0.90 | MGLL (0.42) | TTRALBCYP11B1CYP11B2MGLL | |
| SCHEMBL9987501 | 0.88 | MGLL (0.42) | TTRALBCYP11B1CYP11B2MGLL | |
| SCHEMBL2656346 | 0.88 | TTR (0.35) | TTRALBCYP11B1CYP11B2MGLL | |
| SCHEMBL12332162 | 0.88 | GRIN2D (0.33) | TTRALBCYP11B1CYP11B2MGLL | |
| SCHEMBL12127371 | 0.88 | KCNH2 (0.43) | CYP11B1CYP11B2MGLLGAASMN1; SMN2 | |
| SCHEMBL1336198 | 0.84 | FFAR4 (0.41) | CYP11B1CYP11B2ALDH1A1GAAKMT2A | |
| SCHEMBL25260446 | 0.84 | GRIN2D (0.37) | CYP11B1CYP11B2ALDH1A1GRIN2DGRIN3B | |
| SCHEMBL1875078 | 0.84 | KMT2A (0.51) | ALDH1A1KMT2AGCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170022232-A1 | METHOD FOR IN-SITU FORMATION OF METATHESIS CATALYSTS | SCHRODI YANN (US) | 2017-01-26 | — | — | US | disclosed |
| US-9273081-B2 | Method for in-situ formation of metathesis catalysts | ExxonMobil Product Solutions Company | 2016-03-01 | — | — | US | disclosed |
| US-20150299235-A1 | METHOD FOR IN-SITU FORMATION OF METATHESIS CATALYSTS | ExxonMobil Product Solutions Company | 2015-10-22 | — | — | US | disclosed |
| US-20130204026-A1 | METHOD FOR IN-SITU FORMATION OF METATHESIS CATALYSTS | MATERIA, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| WO-2011119778-A2 | METHOD FOR IN-SITU FORMATION OF METATHESIS CATALYSTS | SCHRODI YANN (US) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299235-A1 | METHOD FOR IN-SITU FORMATION OF METATHESIS CATALYSTS | CHRM1, ACSL1, LOXL1 | TTR 4628/4885ALB 3774/4885CYP11B1 457/4885 |
| US-20170022232-A1 | METHOD FOR IN-SITU FORMATION OF METATHESIS CATALYSTS | CHRM1, ACSL1, LOXL1 | TTR 4628/4885ALB 3774/4885CYP11B1 457/4885 |
| US-20130204026-A1 | METHOD FOR IN-SITU FORMATION OF METATHESIS CATALYSTS | CHRM1, ACSL1, LOXL1 | TTR 4628/4885ALB 3774/4885CYP11B1 457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.